Schroder Investment Management Group Nektar Therapeutics Transaction History

Schroder Investment Management Group

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $304,870 - $449,431	-6,562 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $347,568 - $784,941	-7,515 Reduced 53.38%	6,562 $316,000
Q1 2018 May 11, 2018	BUY	$57.4 - $108.44 $3,501 - $6,614	61 Added 0.44%	14,077 $1.5 Million
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $153,658 - $403,837	6,675 Added 90.93%	14,016 $837,000
Q3 2017 Nov 09, 2017	BUY	$17.79 - $24.0 $130,596 - $176,184	7,341	7,341 $174,000

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.